This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A.: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018; 68: 394-424BrayF.FerlayJ.SoerjomataramI.SiegelR.L.TorreL.A.JemalA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J. Clin20186839442410.3322/caac.2149230207593Search in Google Scholar
Duffy M.J., McKiernan E., O’Donovan N., McGowan P.M.: Role of ADAMs in cancer formation and progression. Clin. Cancer Res., 2009; 15: 1140-1144DuffyM.J.McKiernanE.O’DonovanN.McGowanP.M.Role of ADAMs in cancer formation and progressionClin. Cancer Res2009151140114410.1158/1078-0432.CCR-08-158519228719Search in Google Scholar
Walkiewicz K., Kozieł P., Bednarczyk M., Błażelonis A., Mazurek U., Muc-Wierzgoń M.: Expression of migration-related genes in human colorectal cancer and activity of a disintegrin and metalloproteinase 17. Biomed Res. Int., 2016; 2016: 8208904WalkiewiczK.KoziełP.BednarczykM.BłażelonisA.MazurekU.Muc-WierzgońM.Expression of migration-related genes in human colorectal cancer and activity of a disintegrin and metalloproteinase 17Biomed Res. Int20162016820890410.1155/2016/8208904482667127110571Search in Google Scholar
Walkiewicz K., Nowakowska-Zajdel E., Kozieł P., Muc-Wierzgoń M.: The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancer. Cent. Eur. J. Immunol., 2018; 43: 109-113WalkiewiczK.Nowakowska-ZajdelE.KoziełP.Muc-WierzgońM.The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancerCent. Eur. J. Immunol20184310911310.5114/ceji.2018.74881592718029731694Search in Google Scholar
Fushida S., Oyama K., Kinoshita J., Yagi Y., Okamoto K., Tajima H., Ninomiya I., Fujimura T., Ohta T.: VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: Prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody. Onco. Targets Ther., 2013; 6: 14451451FushidaS.OyamaK.KinoshitaJ.YagiY.OkamotoK.TajimaH.NinomiyaI.FujimuraT.OhtaT.VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: Prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibodyOnco. Targets Ther201361445145110.2147/OTT.S51916380459124204159Search in Google Scholar
Gao M.Q., Kim B.G., Kang S., Choi Y.P., Yoon J.H., Cho N.H.: Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-α cleavage by ADAM17. Cancer Lett., 2013; 336: 240-246GaoM.Q.KimB.G.KangS.ChoiY.P.YoonJ.H.ChoN.H.Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-α cleavage by ADAM17Cancer Lett201333624024610.1016/j.canlet.2013.05.01123684931Search in Google Scholar
Mochizuki S., Okada Y.: ADAM28 as a target for human cancers. Curr. Pharm. Des., 2009; 15: 2349-2358MochizukiS.OkadaY.ADAM28 as a target for human cancersCurr. Pharm. Des2009152349235810.2174/13816120978868242419601836Search in Google Scholar
Stawikowska R., Cudic M., Giulianotti M., Houghten R.A., Fields G.B., Minond D.: Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates. J. Biol. Chem., 2013; 288: 22871-22879StawikowskaR.CudicM.GiulianottiM.HoughtenR.A.FieldsG.B.MinondD.Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substratesJ. Biol. Chem2013288228712287910.1074/jbc.M113.462267382937023779109Search in Google Scholar
Jones J.C., Rustagi S., Dempsey P.J.: ADAM proteases and gastrointestinal function. Annu. Rev. Physiol., 2016; 78: 243-276JonesJ.C.RustagiS.DempseyP.J.ADAM proteases and gastrointestinal functionAnnu. Rev. Physiol20167824327610.1146/annurev-physiol-021014-071720492719426667078Search in Google Scholar
Zhou Z., Ran Y.L., Hu H., Pan J., Li Z.F., Chen L.Z., Sun L.C., Peng L., Zhao X.L., Yu L. i wsp.: TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression. Clin. Exp. Metastasis, 2008; 25: 537-548ZhouZ.RanY.L.HuH.PanJ.LiZ.F.ChenL.Z.SunL.C.PengL.ZhaoX.L.YuL.i wspTM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expressionClin. Exp. Metastasis20082553754810.1007/s10585-008-9168-018365756Search in Google Scholar
Liu H.B., Zhu Y., Yang Q.C., Shen Y., Zhang X.J., Chen H.: Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma. Genet. Mol. Res., 2015; 14: 43914398LiuH.B.ZhuY.YangQ.C.ShenY.ZhangX.J.ChenH.Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinomaGenet. Mol. Res2015144391439810.4238/2015.April.30.1225966212Search in Google Scholar
Lo P.H., Lung H.L., Cheung A.K., Apte S.S., Chan K.W., Kwong F.M., Ko J.M., Cheng Y., Law S., Srivastava G. i wsp.: Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res., 2010; 70: 5567-5576LoP.H.LungH.L.CheungA.K.ApteS.S.ChanK.W.KwongF.M.KoJ.M.ChengY.LawS.SrivastavaG.i wspExtracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesisCancer Res2010705567557610.1158/0008-5472.CAN-09-4510289644420551050Search in Google Scholar
Kauttu T., Mustonen H., Vainionpää S., Krogerus L., Ilonen I., Räsänen J., Salo J., Puolakkainen P.: Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma. Clin. Transl. Oncol., 2017; 19: 58-66KauttuT.MustonenH.VainionpääS.KrogerusL.IlonenI.RäsänenJ.SaloJ.PuolakkainenP.Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinomaClin. Transl. Oncol201719586610.1007/s12094-016-1503-327026568Search in Google Scholar
Yoshimura T., Tomita T., Dixon M.F., Axon A.T., Robinson P.A., Crabtree J.E.: ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori – infected, normal, and neoplastic gastric mucosa. J. Infect. Dis., 2002; 185: 332-340YoshimuraT.TomitaT.DixonM.F.AxonA.T.RobinsonP.A.CrabtreeJ.E.ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori – infected, normal, and neoplastic gastric mucosaJ. Infect. Dis200218533234010.1086/33819111807715Search in Google Scholar
Wang Y.Y., Ye Z.Y., Li L., Zhao Z.S., Shao Q.S., Tao H.Q.: ADAM 10 is associated with gastric cancer progression and prognosis of patients. J. Surg. Oncol., 2011; 103: 116-123WangY.Y.YeZ.Y.LiL.ZhaoZ.S.ShaoQ.S.TaoH.Q.ADAM 10 is associated with gastric cancer progression and prognosis of patientsJ. Surg. Oncol201110311612310.1002/jso.2178121259244Search in Google Scholar
Shou Z.X., Jin X., Zhao Z.S.: Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann. Surg., 2012; 256: 1014-1022ShouZ.X.JinX.ZhaoZ.S.Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancerAnn. Surg20122561014102210.1097/SLA.0b013e3182592f5622668812Search in Google Scholar
Zhang T.C., Zhu W.G., Huang M.D., Fan R.H., Chen X.F.: Prognostic value of ADAM17 in human gastric cancer. Med. Oncol., 2012; 29: 2684-2690ZhangT.C.ZhuW.G.HuangM.D.FanR.H.ChenX.F.Prognostic value of ADAM17 in human gastric cancerMed. Oncol2012292684269010.1007/s12032-011-0125-422139867Search in Google Scholar
Aydin D., Bilici A., Yavuzer D., Kefeli U., Tan A., Ercelep O., Mert A., Yuksel S., Ozcelik M., Isik D. i wsp.: Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy. Clin. Transl. Oncol., 2015; 17: 604-611AydinD.BiliciA.YavuzerD.KefeliU.TanA.ErcelepO.MertA.YukselS.OzcelikM.IsikD.i wspPrognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomyClin. Transl. Oncol20151760461110.1007/s12094-015-1283-125786367Search in Google Scholar
Li W., Wang D., Sun X., Zhang Y., Wang L., Suo J.: ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways. Int. J. Mol. Med., 2019; 43: 914-926LiW.WangD.SunX.ZhangY.WangL.SuoJ.ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathwaysInt. J. Mol. Med20194391492610.3892/ijmm.2018.4028631766630569104Search in Google Scholar
Ebi M., Kataoka H., Shimura T., Kubota E., Hirata Y., Mizushima T., Mizoshita T., Tanaka M., Mabuchi M., Tsukamoto H. i wsp.: TGFβ induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells. Biochem. Biophys. Res. Commun., 2010; 402: 449-454EbiM.KataokaH.ShimuraT.KubotaE.HirataY.MizushimaT.MizoshitaT.TanakaM.MabuchiM.TsukamotoH.i wspTGFβ induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cellsBiochem. Biophys. Res. Commun201040244945410.1016/j.bbrc.2010.09.13020934403Search in Google Scholar
Nakagawa M., Nabeshima K., Asano S., Hamasaki M., Uesugi N., Tani H., Yamashita Y., Iwasaki H.: Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: Coexpression with EGFR and EGFR ligands. Cancer Sci., 2009; 100: 654-662NakagawaM.NabeshimaK.AsanoS.HamasakiM.UesugiN.TaniH.YamashitaY.IwasakiH.Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: Coexpression with EGFR and EGFR ligandsCancer Sci200910065466210.1111/j.1349-7006.2009.01089.x19298600Search in Google Scholar
Carl-McGrath S., Lendeckel U., Ebert M., Roessner A., Röcken C.: The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int. J. Oncol., 2005; 26: 17-24Carl-McGrathS.LendeckelU.EbertM.RoessnerA.RöckenC.The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancerInt. J. Oncol200526172410.3892/ijo.26.1.17Search in Google Scholar
Kim K.E., Song H., Hahm C., Yoon S.Y., Park S., Lee H.R., Hur D.Y., Kim T., Kim C.H., Bang S.I. i wsp.: Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer. J. Immunol., 2009; 182: 3548-3555KimK.E.SongH.HahmC.YoonS.Y.ParkS.LeeH.R.HurD.Y.KimT.KimC.H.BangS.I.i wspExpression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancerJ. Immunol20091823548355510.4049/jimmunol.080169519265133Search in Google Scholar
Kim J.M., Jeung H.C., Rha S.Y., Yu E.J., Kim T.S., Shin Y.K., Zhang X., Park K.H., Park S.W., Chung H.C. i wsp.: The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Mol. Cancer Ther., 2014; 13: 3074-3085KimJ.M.JeungH.C.RhaS.Y.YuE.J.KimT.S.ShinY.K.ZhangX.ParkK.H.ParkS.W.ChungH.C.i wspThe effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progressionMol. Cancer Ther2014133074308510.1158/1535-7163.MCT-13-1001425846325344581Search in Google Scholar
Wang J., Zhou Y., Fei X., Chen X., Yan J., Liu B., Zhu Z.: ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126. Oncol. Rep., 2017; 37: 2033-2040WangJ.ZhouY.FeiX.ChenX.YanJ.LiuB.ZhuZ.ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126Oncol. Rep2017372033204010.3892/or.2017.546028260063Search in Google Scholar
Huang J., Bai Y., Huo L., Xiao J., Fan X., Yang Z., Chen H., Yang Z.: Upregulation of a disintegrin and metalloprotease 8 is associated with progression and prognosis of patients with gastric cancer. Transl. Res., 2015; 166: 602-613HuangJ.BaiY.HuoL.XiaoJ.FanX.YangZ.ChenH.YangZ.Upregulation of a disintegrin and metalloprotease 8 is associated with progression and prognosis of patients with gastric cancerTransl. Res201516660261310.1016/j.trsl.2015.05.00126024798Search in Google Scholar
Chung H.W., Kim J.J., Choi J.I., Lee H.R., Lim J.B.: A disintegrin and metalloproteinase 8 as a potential blood biomarker for early diagnosis of gastric cancer. Yonsei Med. J., 2019; 60: 713-719ChungH.W.KimJ.J.ChoiJ.I.LeeH.R.LimJ.B.A disintegrin and metalloproteinase 8 as a potential blood biomarker for early diagnosis of gastric cancerYonsei Med. J20196071371910.3349/ymj.2019.60.8.713666044531347325Search in Google Scholar
Chen H., Wang S.: Clinical significance of ADAM29 promoting the invasion and growth of gastric cancer cells in vitro. Oncol. Lett., 2018; 16: 1483-1490ChenH.WangS.Clinical significance of ADAM29 promoting the invasion and growth of gastric cancer cells in vitroOncol. Lett2018161483149010.3892/ol.2018.8838603646530008827Search in Google Scholar
Ilic M, Ilic I.: Epidemiology of pancreatic cancer. World J. Gastroenterol., 2016; 22: 9694-9705IlicMIlicI.Epidemiology of pancreatic cancerWorld J. Gastroenterol2016229694970510.3748/wjg.v22.i44.9694512497427956793Search in Google Scholar
Stewart B.W., Wild C.P.: World cancer report 2014. International Agency for Research on Cancer, Lyon 2014StewartB.W.WildC.P.World cancer report 2014. International Agency for Research on CancerLyon2014Search in Google Scholar
Gaida M.M., Haag N., Günther F., Tschaharganeh D.F., Schirmacher P., Friess H., Giese N.A., Schmidt J., Wente M.N.: Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int. J. Mol. Med., 2010; 26: 281-288GaidaM.M.HaagN.GüntherF.TschaharganehD.F.SchirmacherP.FriessH.GieseN.A.SchmidtJ.WenteM.N.Expression of A disintegrin and metalloprotease 10 in pancreatic carcinomaInt. J. Mol. Med20102628128810.3892/ijmm_00000463Search in Google Scholar
Ringel J., Jesnowski R., Moniaux N., Lüttges J., Ringel J., Choudhury A., Batra S.K., Klöppel G., Löhr M.: Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-α converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res., 2006; 66: 9045-9053RingelJ.JesnowskiR.MoniauxN.LüttgesJ.RingelJ.ChoudhuryA.BatraS.K.KlöppelG.LöhrM.Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-α converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinomaCancer Res2006669045905310.1158/0008-5472.CAN-05-328716982746Search in Google Scholar
Valkovskaya N., Kayed H., Felix K., Hartmann D., Giese N.A., Osinsky S.P., Friess H., Kleeff J.: ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J. Cell. Mol. Med., 2007; 11: 1162-1174ValkovskayaN.KayedH.FelixK.HartmannD.GieseN.A.OsinskyS.P.FriessH.KleeffJ.ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancerJ. Cell. Mol. Med2007111162117410.1111/j.1582-4934.2007.00082.x440127717979891Search in Google Scholar
Valkovskaya N.V: Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines. Exp. Oncol., 2008; 30: 129132ValkovskayaN.VHypoxia-dependent expression of ADAM8 in human pancreatic cancer cell linesExp. Oncol200830129132Search in Google Scholar
Puolakkainen P., Koski A., Vainionpää S., Shen Z., Repo H., Kemppainen E., Mustonen H., Seppänen H.: Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression. Med. Oncol., 2014; 31: 884PuolakkainenP.KoskiA.VainionpääS.ShenZ.RepoH.KemppainenE.MustonenH.SeppänenH.Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expressionMed. Oncol20143188410.1007/s12032-014-0884-924526468Search in Google Scholar
Gao Y., Yu X., Zhang F., Dai J.: Propofol inhibits pancreatic cancer progress under hypoxia via ADAM8. J. Hepatobiliary Pancreat. Sci., 2019; 26: 219-226GaoY.YuX.ZhangF.DaiJ.Propofol inhibits pancreatic cancer progress under hypoxia via ADAM8J. Hepatobiliary Pancreat. Sci20192621922610.1002/jhbp.62430945470Search in Google Scholar
Grützmann R., Lüttges J., Sipos B., Ammerpohl O., Dobrowolski F., Alldinger I., Kersting S., Ockert D., Koch R., Kalthoff H. i wsp.: ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br. J. Cancer, 2004; 90: 1053-1058GrützmannR.LüttgesJ.SiposB.AmmerpohlO.DobrowolskiF.AlldingerI.KerstingS.OckertD.KochR.KalthoffH.i wspADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinomaBr. J. Cancer2004901053105810.1038/sj.bjc.6601645240962514997207Search in Google Scholar
Oria V.O., Lopatta P., Schmitz T., Preca B.T., Nyström A., Conrad C., Bartsch J.W., Kulemann B., Hoeppner J., Maurer J. i wsp.: ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma. Mol. Oncol., 2019; 13: 456-479OriaV.O.LopattaP.SchmitzT.PrecaB.T.NyströmA.ConradC.BartschJ.W.KulemannB.HoeppnerJ.MaurerJ.i wspADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinomaMol. Oncol20191345647910.1002/1878-0261.12426636037330556643Search in Google Scholar
Duan X., Mao X., Sun W.: ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells. Mol. Med. Rep., 2013; 7: 991-997DuanX.MaoX.SunW.ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cellsMol. Med. Rep2013799199710.3892/mmr.2013.127223314034Search in Google Scholar
Woods N., Trevino J., Coppola D., Chellappan S., Yang S., Padmanabhan J.: Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling. Oncotarget, 2015; 6: 35931-35948WoodsN.TrevinoJ.CoppolaD.ChellappanS.YangS.PadmanabhanJ.Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signalingOncotarget20156359313594810.18632/oncotarget.5933474215226440150Search in Google Scholar
Ye J., Yuen S.M., Murphy G., Xie R., Kwok H.F.: Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo. Eur. J. Pharm. Sci., 2017; 110: 62-69YeJ.YuenS.M.MurphyG.XieR.KwokH.F.Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo. EurJ. Pharm. Sci2017110626910.1016/j.ejps.2017.05.057Search in Google Scholar
Schlomann U., Koller G., Conrad C., Ferdous T., Golfi P., Garcia A.M., Höfling S., Parsons M., Costa P., Soper R. i wsp.: ADAM8 as a drug target in pancreatic cancer. Nat. Commun., 2015; 6: 6175SchlomannU.KollerG.ConradC.FerdousT.GolfiP.GarciaA.M.HöflingS.ParsonsM.CostaP.SoperR.i wspADAM8 as a drug target in pancreatic cancerNat. Commun20156617510.1038/ncomms7175501412325629724Search in Google Scholar
Moss M.L., Minond D.: Recent advances in ADAM17 research: A promising target for cancer and inflammation. Mediators Inflamm., 2017; 2017: 9673537MossM.L.MinondD.Recent advances in ADAM17 research: A promising target for cancer and inflammationMediators Inflamm20172017967353710.1155/2017/9673537568826029230082Search in Google Scholar
Terzić J., Grivennikov S., Karin E., Karin M.: Inflammation and colon cancer. Gastroenterology, 2010; 138: 2101-2114TerzićJ.GrivennikovS.KarinE.KarinM.Inflammation and colon cancerGastroenterology20101382101211410.1053/j.gastro.2010.01.05820420949Search in Google Scholar
Blanchot-Jossic F., Jarry A., Masson D., Bach-Ngohou K., Paineau J., Denis M.G., Laboisse C.L., Mosnier J.F.: Up-regulated expression of ADAM17 in human colon carcinoma: Co-expression with EGFR in neoplastic and endothelial cells. J. Pathol., 2005; 207: 156-163Blanchot-JossicF.JarryA.MassonD.Bach-NgohouK.PaineauJ.DenisM.G.LaboisseC.L.MosnierJ.F.Up-regulated expression of ADAM17 in human colon carcinoma: Co-expression with EGFR in neoplastic and endothelial cellsJ. Pathol200520715616310.1002/path.181416041691Search in Google Scholar
Das S., Czarnek M., Bzowska M., Mężyk-Kopeć R., Stalińska K., Wyroba B., Sroka J., Jucha J., Deneka D., Stokłosa P. i wsp.: ADAM17 silencing in mouse colon carcinoma cells: The effect on tumoricidal cytokines and angiogenesis. PLoS One, 2012; 7: e50791DasS.CzarnekM.BzowskaM.Mężyk-KopećR.StalińskaK.WyrobaB.SrokaJ.JuchaJ.DenekaD.StokłosaP.i wspADAM17 silencing in mouse colon carcinoma cells: The effect on tumoricidal cytokines and angiogenesisPLoS One20127e5079110.1371/journal.pone.0050791351946923251384Search in Google Scholar
Lin H.M., Chatterjee A., Lin Y.H., Anjomshoaa A., Fukuzawa R., McCall J.L., Reeve A.E.: Genome wide expression profiling identifies genes associated with colorectal liver metastasis. Oncol. Rep., 2007; 17: 1541-1549LinH.M.ChatterjeeA.LinY.H.AnjomshoaaA.FukuzawaR.McCallJ.L.ReeveA.E.Genome wide expression profiling identifies genes associated with colorectal liver metastasisOncol. Rep2007171541154910.3892/or.17.6.154117487416Search in Google Scholar
Van Schaeybroeck S., Kyula J.N., Fenton A., Fenning C.S., Sasazuki T., Shirasawa S., Longley D.B., Johnston P.G.: Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res., 2011; 71: 1071-1080VanSchaeybroeck S.KyulaJ.N.FentonA.FenningC.S.SasazukiT.ShirasawaS.LongleyD.B.JohnstonP.G.Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17Cancer Res2011711071108010.1158/0008-5472.CAN-10-0714307312621148749Search in Google Scholar
Rios-Doria J., Sabol D., Chesebrough J., Stewart D., Xu L., Tammali R., Cheng L., Du Q., Schifferli K., Rothstein R. i wsp.: A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways. Mol. Cancer Ther., 2015; 14: 1637-1649Rios-DoriaJ.SabolD.ChesebroughJ.StewartD.XuL.TammaliR.ChengL.DuQ.SchifferliK.RothsteinR.i wspA monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathwaysMol. Cancer Ther2015141637164910.1158/1535-7163.MCT-14-104025948294Search in Google Scholar
Dempsey P.J.: Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis. Biochim. Biophys. Acta, 2017; 1864: 22282239DempseyP.J.Role of ADAM10 in intestinal crypt homeostasis and tumorigenesisBiochim. Biophys. Acta201718642228223910.1016/j.bbamcr.2017.07.011563258928739265Search in Google Scholar
Knösel T., Emde A., Schlüns K., Chen Y., Jürchott K., Krause M., Dietel M., Petersen I.: Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia, 2005; 7: 741-747KnöselT.EmdeA.SchlünsK.ChenY.JürchottK.KrauseM.DietelM.PetersenI.Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancerNeoplasia2005774174710.1593/neo.05178150188316207476Search in Google Scholar
Walkiewicz K., Strzelczyk J., Waniczek D., Biernacki K., Muc-Wierzgoń M., Copija A., Nowakowska-Zajdel E.: Adamalysines as biomarkers and a potential target of therapy in colorectal cancer patients: Preliminary results. Dis. Markers, 2019; 2019: 5035234WalkiewiczK.StrzelczykJ.WaniczekD.BiernackiK.Muc-WierzgońM.CopijaA.Nowakowska-ZajdelE.Adamalysines as biomarkers and a potential target of therapy in colorectal cancer patients: Preliminary resultsDis. Markers20192019503523410.1155/2019/5035234674517331565100Search in Google Scholar
Nowakowska-Zajdel E., Mazurek U., Wierzgoń J., Kokot T., Fatyga E., Ziółko E., Klakla K., Błazelonis A., Waniczek D., Głogowski Ł. i wsp.: Expression of ADAM28 and IGFBP-3 genes in patients with colorectal cancer – a preliminary report. Int. J. Immunopathol. Pharmacol., 2013; 26: 223-228Nowakowska-ZajdelE.MazurekU.WierzgońJ.KokotT.FatygaE.ZiółkoE.KlaklaK.BłazelonisA.WaniczekD.GłogowskiŁ.i wspExpression of ADAM28 and IGFBP-3 genes in patients with colorectal cancer – a preliminary reportInt. J. Immunopathol. Pharmacol20132622322810.1177/03946320130260012223527725Search in Google Scholar
Mochizuki S., Ao T., Sugiura T., Yonemura K., Shiraishi T., Kajiwara Y., Okamoto K., Shinto E., Okada Y., Ueno H.: Expression and function of a disintegrin and metalloproteinases in cancerassociated fibroblasts of colorectal cancer. Digestion, 2020; 101: 18-24MochizukiS.AoT.SugiuraT.YonemuraK.ShiraishiT.KajiwaraY.OkamotoK.ShintoE.OkadaY.UenoH.Expression and function of a disintegrin and metalloproteinases in cancerassociated fibroblasts of colorectal cancerDigestion2020101182410.1159/00050408731722362Search in Google Scholar
Yang Z., Bai Y., Huo L., Chen H., Huang J., Li J., Fan X., Yang Z., Wang L., Wang J.: Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer. BMC Cancer, 2014; 14: 568YangZ.BaiY.HuoL.ChenH.HuangJ.LiJ.FanX.YangZ.WangL.WangJ.Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancerBMC Cancer20141456810.1186/1471-2407-14-568414108825098630Search in Google Scholar
Hirao T., Nanba D., Tanaka M., Ishiguro H., Kinugasa Y., Doki Y., Yano M., Matsuura N., Monden M., Higashiyama S.: Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp. Cell Res., 2006; 312: 331-339HiraoT.NanbaD.TanakaM.IshiguroH.KinugasaY.DokiY.YanoM.MatsuuraN.MondenM.HigashiyamaS.Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cellsExp. Cell Res200631233133910.1016/j.yexcr.2005.10.03216336960Search in Google Scholar
Mazzocca A., Coppari R., De Franco R., Cho J.Y., Libermann T.A., Pinzani M., Toker A.: A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res., 2005; 65: 4728-4738MazzoccaA.CoppariR.De FrancoR.ChoJ.Y.LibermannT.A.PinzaniM.TokerA.A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactionsCancer Res2005654728473810.1158/0008-5472.CAN-04-444915930291Search in Google Scholar
Toquet C., Colson A., Jarry A., Bezieau S., Volteau C., Boisseau P., Merlin D., Laboisse C.L., Mosnier J.F.: ADAM15 to α5β1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosis. Int. J. Cancer, 2012; 130: 278-287ToquetC.ColsonA.JarryA.BezieauS.VolteauC.BoisseauP.MerlinD.LaboisseC.L.MosnierJ.F.ADAM15 to α5β1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosisInt. J. Cancer201213027828710.1002/ijc.2589121190186Search in Google Scholar
Wang J., Li H., Wang Y., Wang L., Yan X., Zhang D., Ma X., Du Y., Liu X., Yang Y.: MicroRNA-552 enhances metastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28. Oncotarget, 2016; 7: 70194-70210WangJ.LiH.WangY.WangL.YanX.ZhangD.MaX.DuY.LiuX.YangY.MicroRNA-552 enhances metastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28Oncotarget20167701947021010.18632/oncotarget.12169534254627661126Search in Google Scholar
Li L.X., Lam I.H., Liang F.F., Yi S.P., Ye L.F., Wang J.T., Guo W.W., Xu M.: MiR-198 affects the proliferation and apoptosis of colorectal cancer through regulation of ADAM28/JAK-STAT signaling pathway. Eur. Rev. Med. Pharmacol. Sci., 2019; 23: 1487-1493LiL.X.LamI.H.LiangF.F.YiS.P.YeL.F.WangJ.T.GuoW.W.XuM.MiR-198 affects the proliferation and apoptosis of colorectal cancer through regulation of ADAM28/JAK-STAT signaling pathwayEur. Rev. Med. Pharmacol. Sci20192314871493Search in Google Scholar
Zhang Q., Yu L., Qin D., Huang R., Jiang X., Zou C., Tang Q., Chen Y., Wang G., Wang X., Gao X.: Role of microRNA-30c targeting ADAM19 in colorectal cancer. PLoS One, 2015; 10: e0120698ZhangQ.YuL.QinD.HuangR.JiangX.ZouC.TangQ.ChenY.WangG.WangX.GaoX.Role of microRNA-30c targeting ADAM19 in colorectal cancerPLoS One201510e012069810.1371/journal.pone.0120698437075725799050Search in Google Scholar
Fu Q., Cheng J., Zhang J., Zhang Y., Chen X., Luo S., Xie J.: MiR-20b reduces 5-FU resistance by suppressing the ADAM9/ EGFR signaling pathway in colon cancer. Oncol. Rep., 2017; 37: 123-130FuQ.ChengJ.ZhangJ.ZhangY.ChenX.LuoS.XieJ.MiR-20b reduces 5-FU resistance by suppressing the ADAM9/ EGFR signaling pathway in colon cancerOncol. Rep20173712313010.3892/or.2016.525927878272Search in Google Scholar
Carloni V., Mazzocca A., Mello T., Galli A., Capaccioli S.: Cell fusion promotes chemoresistance in metastatic colon carcinoma. Oncogene, 2013; 32: 2649-2660CarloniV.MazzoccaA.MelloT.GalliA.CapaccioliS.Cell fusion promotes chemoresistance in metastatic colon carcinomaOncogene2013322649266010.1038/onc.2012.26822751128Search in Google Scholar
Kyula J.N., Van Schaeybroeck S., Doherty J., Fenning C.S., Longley D.B., Johnston P.G.: Chemotherapy-induced activation of ADAM-17: A novel mechanism of drug resistance in colorectal cancer. Clin. Cancer Res., 2010; 16: 3378-3389KyulaJ.N.VanSchaeybroeck S.DohertyJ.FenningC.S.LongleyD.B.JohnstonP.G.Chemotherapy-induced activation of ADAM-17: A novel mechanism of drug resistance in colorectal cancerClin. Cancer Res2010163378338910.1158/1078-0432.CCR-10-0014289655020570921Search in Google Scholar